Jump to main content
Jump to site search


Recent Advances in Combretastatin Based Derivatives and Prodrugs as Antimitotic Agents

Abstract

The dynamic and crucial role of tubulin in different cellular functions rendered it to become a promising target in anticancer drug development. Combretastatin A-4 (CA-4), an inhibitor of tubulin polymerization, isolated from natural source is a lead molecule with significant cytotoxicity against tumour. Owing to its non polar nature it exhibit low solubility in natural biological fluids, thereby prompting development of new CA-4 based derivatives. The modification of this lead molecule was mostly carried out by keeping the crucial cis-orientation of double bond intact, along with a trimethoxyphenyl aromatic ring by employing different approaches. The issue of solubility was also addressed by the development of water soluble prodrugs of CA-4. The present review highlights the investigations in the parallel development of both new CA-4 based derivative as well as prodrugs in last few years.

Back to tab navigation

Publication details

The article was received on 03 May 2017, accepted on 03 Jul 2017 and first published on 04 Jul 2017


Article type: Review Article
DOI: 10.1039/C7MD00227K
Citation: Med. Chem. Commun., 2017, Accepted Manuscript
  •   Request permissions

    Recent Advances in Combretastatin Based Derivatives and Prodrugs as Antimitotic Agents

    Z. S. Seddigi, M. S. Malik, P. S. A , S. Ahmed, A. O. Babalghith, H. A. Lamfon and A. Kamal, Med. Chem. Commun., 2017, Accepted Manuscript , DOI: 10.1039/C7MD00227K

Search articles by author

Spotlight

Advertisements